bitsensing and Stress Solution Partner on Integrated Healthcare Model
Radar solutions company bitsensing has signed a strategic MOU with AI digital healthcare firm Stress Solution to develop an integrated healthcare model that combines biometric monitoring with personalized wellness interventions. The partnership will merge bitsensing’s radar-based sleep and occupancy sensing technology with Stress Solution’s HRV-based personalized sound platform to create a system that connects measurement, analysis, intervention, and feedback.

As an initial project, the companies will collaborate on a smart showroom that automatically adjusts lighting, media, and personalized sound experiences based on user presence and condition. The partners also plan to expand their solutions into senior care, corporate wellness, smart housing, and hospitality markets, with the goal of delivering personalized wellness experiences that encourage long- term behavioral change and improved health outcomes.

bitsensing has signed a MOU with Stress Solution to develop an integrated healthcare model that combines biometric monitoring with personalized wellness interventions.

“Sleep data plays an important role in understanding a user’s condition, but intervention and routine formation are essential for actual improvement,” said Dr. Jae-Eun Lee, CEO of bitsensing. “Through our collaboration with Stress Solution, we will provide differentiated healthcare services.”

Bae Ik-ryeol, CEO of Stress Solution, said: “Personalized sound technology based on biometric data becomes more effective the more precisely it operates in accordance with the user’s condition. Through this collaboration, we will create a new healthcare experience that users can truly feel in real spaces.”

Moon Rabbit Earns Second Consecutive Great Place To Work Certification
Moon Rabbit has earned its second consecutive Great Place To Work® Certification, with employee survey scores increasing across all measured categories compared with 2025.

The independent healthcare and pharma agency reported an average seven-point improvement overall and met or exceeded Top 100 workplace benchmarks in 10 categories, including camaraderie, integrity, leadership behavior, and workplace relationships. The largest year-over-year gain was in community, which increased by more than 20 points, reflecting the agency’s continued focus on culture, transparency, and employee engagement.

“In this industry, the work is only as good as the people making it. When your team is ambitious, curious, respectful, and trusts each other, it makes a difference in the thinking, the work, and the client experience,” said James Tinker, Managing Partner, Moon Rabbit. “Two years running, the team here is proving that to be right.”

PrescriberPoint Launches AI-Powered Prior Authorization Platform
PrescriberPoint has announced an agentic AI prior authorization (PA) solution designed to automate the entire authorization process from prescribing through payer approval, appeals, and pharmacy routing. In a clinical validation study involving 1,289 PA responses, the platform achieved a 94.5% clinician acceptance rate for AIgenerated submissions, including one specialty medication case in which the AI autonomously completed 163 payer questions. Embedded directly within the prescribing workflow, the solution leverages clinical and payer data to streamline documentation, eligibility verification, and benefit checks, helping some patients begin complex therapies in as little as 48 hours. The platform also provides pharmaceutical manufacturers with greater visibility into patient access barriers and authorization outcomes, supporting efforts to improve therapy access and reduce treatment delays.

“The PA process has been a black box—for prescribers, for patients, and especially for the brands whose therapies depend on getting through it,” said Dan Cornwell, CEO of PrescriberPoint. “Our AI agent doesn’t just fill out forms. It understands what each payer requires, assembles the clinical evidence, and gets patients started on therapy faster. The results are very exciting—and the clinicians and brands we are working with are telling us this is a game changer for them.”

Xcovery Selects EVERSANA to Support U.S. Launch of ENSACOVE
Xcovery Holdings, Inc. has partnered with EVERSANA to support and expand the US commercialization of ENSACOVE (ensartinib), a next-generation ALK inhibitor for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Under the agreement, EVERSANA will provide a full range of commercialization services, including agency of record support, market access, and commercial and medical teams, to help increase patient access to the therapy across the US. ENSACOVE was jointly developed by Xcovery and Betta Pharmaceuticals and is approved for previously untreated patients with ALK-positive advanced NSCLC identified through an FDAapproved test.

“The approval of Ensartinib was a major milestone in our mission to advance precision oncology,” said Giovanni Selvaggi, MD, Chief Medical Officer of Xcovery Holdings, Inc. “As we expand the US launch of ENSACOVE, we are focused on ensuring that patients and providers have the support they need. EVERSANA brings highly experienced, scalable commercialization capabilities, and we’re pleased to partner with them to broaden patient access.”

Alaqua Marketing Unveils ClearPath Experiential DTC Framework for Pharma Brands
Alaqua Marketing LLC has launched ClearPath, a proprietary experiential direct-to-consumer (DTC) framework designed to help pharmaceutical brands engage patients and caregivers in everyday consumer environments while remaining compliant with FDA guidelines. The model places immersive brand experiences in locations such as shopping centers, community venues, and lifestyle destinations, creating structured engagement opportunities outside traditional advertising and healthcare settings. Built around sponsorship and help-seeking advertising principles, ClearPath is intended to provide pharmaceutical marketers, medical affairs teams, and strategic partners with a new approach to patient engagement that avoids many of the regulatory and disclosure challenges associated with conventional DTC marketing channels.

“The pharma industry doesn’t have a compliance problem. It has a creativity problem. ClearPath proves that FDAaware marketing and genuine patient engagement aren’t mutually exclusive—they’re the same opportunity.” said Perry DeGregorio, Founder & CXO, Alaqua Marketing LLC.

“The pharma industry doesn’t have a compliance problem. It has a creativity problem. ClearPath proves that FDA-aware marketing and genuine patient engagement aren’t mutually exclusive—they’re the same opportunity.”

DeepIntent Integrates OptimizeRx’s EHR Network to Expand Point-of-Care Advertising
DeepIntent has become the first healthcare DSP to integrate the authenticated electronic health record (EHR) network of OptimizeRx, expanding access to point-of-care advertising opportunities for life sciences marketers. The collaboration allows brands to activate advertising within healthcare provider workflows using existing programmatic mediabuying tools, while supporting privacy-conscious engagement tied to real clinical decision-making moments. By combining DeepIntent’s healthcare-focused audience targeting and campaign optimization capabilities with OptimizeRx’s proprietary EHR inventory, the partnership aims to help marketers extend omnichannel campaigns into clinical environments and improve provider engagement across the care journey.

“We’re excited to bring OptimizeRx’s industry-leading EHR network to our established client base of pharmaceutical brands, healthcare agencies, and enterprise marketers,” said Lisa Kopp Johnson, Chief Revenue Officer, DeepIntent. “By offering scalable access to providers directly within their clinical workflows, we can help deliver more timely and relevant information that supports informed care decisions and better patient outcomes. This partnership comes as DeepIntent is building the richest marketplace of vital inventory relevant to our clients.”